Study period 1/1/2021 to 10/1/2024 with follow-up possible through 7/1/2025 Study population: inclusion Patients with: PCOS (encounter or billing diagnosis with ICD-10-CM code E28.2) before exposure or within two years of drug trial start Evaluated sex of female or ambiguous Aged 18 to 50 at drug trial start No overlap in metformin and GLP-1 use At least one measurement within one year prior to trial start At least one measurement 9 to 15 months after trial start At least 70% of days covered by their exposure medication dispense Study population: exclusion Patients with: Evidence of pregnancy during baseline or outcome measurements Definitive pregnancy start date: Between 12 months before the first reading through the follow-up reading Definitive pregnancy end date, delivery, or if its ambiguous what point in the pregnancy the patient would be at (e.g
With our expert medical guidance, you can get to the root of hormonal imbalances contributing to your symptoms and start looking and feeling like your younger self again
A patient losing weight steadily at 1.0 mg weekly has no clinical reason to escalate
The same habits that support planning for life after a GLP-1, protein intake, strength training, and steady routines, make both the medication and any future taper work better
" In July 2024, Haytayan took her first GLP-1 shot
Current options like birth control, lifestyle changes and the diabetes drug Metformin may only help with certain symptoms, which could differ depending on the patient
